Preclinical development of a protocol for the manufacturing of anti-CD5 CAR-T lymphocytes for the treatment of T-lineage acute lymphoblastic leukemia and lymphoma
Authors:
- Elvira Y. MusaevaEMElvira Y. Musaeva
- Ekaterina A. MalakhovaEMEkaterina A. Malakhova
- Victoria A. VedmedskaiaVVVictoria A. Vedmedskaia
- Daria S. OsipovaDODaria S. Osipova
- Dmitry V. VolkovDVDmitry V. Volkov
- Alexandr S. ChernovACAlexandr S. Chernov
- Anna S. FedorovaAFAnna S. Fedorova
- Mariia S. FadeevaMFMariia S. Fadeeva
- Oiuna B. LodoevaOLOiuna B. Lodoeva
- Elena A. KulakovskayaEKElena A. Kulakovskaya
- Tatiana A. SozonovaTSTatiana A. Sozonova
- Alexey V. StepanovASAlexey V. Stepanov
Open Access
- 30 June 2025
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 14-26
Abstract
The development of cell therapy methods for T-lineage acute lymphoblastic leukemia remains a relevant clinical challenge. The current study presents a preclinical stage of anti-CD5 CAR-T cell development without the use of additional genetic modifications, relying on down-regulation of CD5. The resulting cell products demonstrated sufficient expansion rates and CAR expression levels, the predominance of the Tem phenotype (CD197–CD45RA–) and low expression of exhaustion markers (PD-1, CD57, TIGIT). The antitumor function was confirmed both in vitro through the assessment of degranulation, cytokine production, and cytotoxicity against the Jurkat cell line, and in vivo through the evaluation of CD5+ leukemia elimination in a murine model. The data obtained may serve as a basis for the development of a clinical manufacturing protocol for anti-CD5 CAR-T cells. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.Keywords
This publication has 27 references indexed in Scilit:
- Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphomaAnnals of Hematology, 2024
- Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicityCell Reports Medicine, 2024
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLeukemia, 2024
- Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process durationCytotherapy, 2024
- Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphomaAnnals of Hematology, 2023
- Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsNature Communications, 2021
- The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domainsMolecular Therapy, 2021
- The multiple faces of CD5Journal of Leukocyte Biology, 2019
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignanciesLeukemia, 2018
- Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell linesOncoImmunology, 2017